Numerous studies have shown that elevated plasma ACE2 levels could be used as a novel biological predictor of abnormal myocardial structure and/or adverse events in cardiometabolic diseases involving HF, myocardial infarction, aortic stenosis, atrial fibrillation, coronary artery disease, and stroke. The gene discussed is ACE2; the disease is myocardial infarction.